Edge Therapeutics Inc (EDGE) Insider Sells $73,950.00 in Stock
Edge Therapeutics Inc (NASDAQ:EDGE) insider Brian A. Leuthner sold 7,500 shares of the stock in a transaction that occurred on Tuesday, December 5th. The stock was sold at an average price of $9.86, for a total transaction of $73,950.00. Following the sale, the insider now owns 95,236 shares in the company, valued at approximately $939,026.96. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Edge Therapeutics Inc (NASDAQ EDGE) traded down $0.21 during midday trading on Tuesday, hitting $9.55. 78,884 shares of the company traded hands, compared to its average volume of 62,801. The company has a current ratio of 8.34, a quick ratio of 8.34 and a debt-to-equity ratio of 0.20. Edge Therapeutics Inc has a twelve month low of $7.30 and a twelve month high of $13.50.
Edge Therapeutics (NASDAQ:EDGE) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.11. equities analysts expect that Edge Therapeutics Inc will post -1.7 EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Franklin Resources Inc. boosted its position in shares of Edge Therapeutics by 1.1% during the 2nd quarter. Franklin Resources Inc. now owns 2,663,123 shares of the biotechnology company’s stock worth $27,324,000 after acquiring an additional 30,100 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Edge Therapeutics during the 2nd quarter worth approximately $21,962,000. Vanguard Group Inc. boosted its position in shares of Edge Therapeutics by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 700,003 shares of the biotechnology company’s stock worth $6,377,000 after acquiring an additional 19,973 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Edge Therapeutics by 223.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 379,075 shares of the biotechnology company’s stock worth $4,063,000 after acquiring an additional 261,850 shares in the last quarter. Finally, Sphera Funds Management LTD. boosted its position in shares of Edge Therapeutics by 122.5% during the 3rd quarter. Sphera Funds Management LTD. now owns 333,737 shares of the biotechnology company’s stock worth $3,581,000 after acquiring an additional 183,737 shares in the last quarter. Institutional investors and hedge funds own 50.26% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/05/edge-therapeutics-inc-edge-insider-sells-73950-00-in-stock.html.
Edge Therapeutics Company Profile
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
Receive News & Ratings for Edge Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.